Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This phase I study will involve escalating doses of CAMPATH until the goal dose for the
cohort is tolerated. The CAMPATH goal dose will be administered to the patient subcutaneously
(SQ) 3 times per week for up to 12 weeks.